If your primary care doctor has ever said “progesterone is progesterone, they’re all the same,” they were wrong. They were not lying. They were repeating a simplification that most pharmacy training treats as accurate enough for practical purposes. For most prescribing situations, that simplification holds. For hormone therapy in perimenopause and menopause, it does not.
Progesterone and progestin are two different categories of molecules. They are made differently, they fit receptors differently, and they produce different effects in breast tissue, in the brain, and in the cardiovascular system. The patient who feels off on a synthetic progestin and feels much better on bioidentical progesterone is not imagining it. The molecules are not interchangeable.
This post breaks down the actual difference and why it matters for anyone making a hormone therapy decision.
Progesterone: What Your Body Already Knows
Progesterone is the hormone the ovaries produce in the second half of the menstrual cycle, after ovulation. It is also produced in smaller amounts by the adrenal glands and, during pregnancy, by the placenta. The molecule has a specific shape and a specific binding profile at the progesterone receptor.
In the body, progesterone does several things that are not always discussed in primary care visits. It opposes the proliferative effect of estrogen on the endometrium, which is part of why it is prescribed to women on estrogen therapy who still have a uterus. It also has effects on the brain that go beyond its reproductive role. Specifically, progesterone is metabolized into a compound called allopregnanolone, which is an active modulator of the GABA-A receptor.
That GABA modulation is why oral micronized progesterone, taken at bedtime, often helps women with sleep onset and sleep maintenance. It is also part of why dropping progesterone in early perimenopause produces new-onset anxiety and sleep loss that women have not previously experienced. The mechanism is not in the patient’s head. It is in the GABA system.
The most common form of bioidentical progesterone used clinically is oral micronized progesterone, sold as Prometrium (brand) or in generic form. It is also available compounded in capsules, troches, or topical preparations.
Progestin: The Synthetic Workaround
Progestins are a category of synthetic compounds engineered to bind the progesterone receptor and produce some of progesterone’s effects. They are not the same molecule. They were developed for specific reasons: oral bioavailability, patent protection, and (in some cases) selective effects that were considered desirable for contraception or specific gynecologic conditions.
The progestins commonly encountered in clinical practice include:
Medroxyprogesterone acetate (MPA), sold as Provera. This is the progestin used in the Women’s Health Initiative combined-therapy arm.
Norethindrone and norethindrone acetate, used in some oral contraceptives and in some hormone therapy preparations.
Levonorgestrel, used in some oral contraceptives and in the Mirena IUD.
Drospirenone, used in some oral contraceptives and in some menopause hormone therapy preparations.
Norgestimate and desogestrel, used primarily in oral contraceptives.
These compounds share the property of binding the progesterone receptor and producing endometrial protection. They differ in their other binding profiles, which is where the clinical differences emerge.
The Receptor Binding Problem
Bioidentical progesterone binds the progesterone receptor relatively cleanly. It has minimal interaction with other steroid receptors. This is a feature of the actual hormone the body uses.
Progestins, in contrast, often bind multiple receptor types in addition to the progesterone receptor. Depending on the specific progestin, this can include:
The androgen receptor, which can produce side effects like acne, hair changes, and mood shifts.
The glucocorticoid receptor, which can affect glucose metabolism and stress response signaling.
The mineralocorticoid receptor, which can affect blood pressure and fluid balance.
Each individual progestin has its own binding profile, which is why the side effect patterns of different progestins differ. Medroxyprogesterone acetate has notable glucocorticoid activity and androgenic effects. Drospirenone has anti-mineralocorticoid activity. Levonorgestrel has notable androgenic activity.
For a patient who has experienced unwanted symptoms on a synthetic progestin (mood changes, fluid retention, acne, hair thinning), the explanation is usually in this binding profile. The molecule is producing effects through receptors that progesterone itself would not significantly activate.
What the Breast Tissue Data Shows
The Women’s Health Initiative combined arm was the source of the original concern about hormone therapy and breast cancer risk. The protocol in that arm used conjugated equine estrogen plus medroxyprogesterone acetate. The estrogen-only arm of the same study did not show the same increased risk, which raised the question of whether the progestin (not the estrogen) was driving much of the breast cancer signal.
Subsequent observational research has explored this question more directly. The E3N cohort study, a large French observational study, tracked women using different hormone therapy protocols. The study found a different breast cancer risk profile for women using bioidentical progesterone with estradiol compared to women using synthetic progestins with estradiol. The bioidentical progesterone group had a notably more favorable profile.
This is observational data and has the usual limitations. Observational findings cannot prove causation the way a randomized trial can. But the pattern has been consistent across multiple studies, and it lines up with the receptor binding biology. The progesterone receptor is one thing. The androgen receptor activation that some synthetic progestins produce in breast tissue is a different thing. The breast tissue evidence has not been ignored by the major menopause societies, and current clinical practice in optimization medicine generally favors bioidentical progesterone for this reason. We covered the broader hormone therapy evidence reframing in our WHI study breakdown.
The Sleep and Mood Difference
The other clinical area where the two categories diverge sharply is sleep and mood.
Oral micronized progesterone, taken at bedtime, produces a metabolite (allopregnanolone) that activates the GABA-A receptor. This is the same receptor system that benzodiazepines activate. The effect is much milder, with no significant addiction potential at therapeutic doses, but the calming and sleep-supporting effect is real and well-documented. Many women on bioidentical progesterone report it as one of the most noticeable benefits of their hormone therapy.
Synthetic progestins do not produce this metabolite in the same way. They do not have the same GABA-modulating effect. Some progestins (depending on the specific molecule) can actually produce mood changes in the other direction (irritability, low mood, anxiety) in susceptible individuals.
For a perimenopausal woman whose primary symptoms include sleep loss and anxiety, this difference is not trivial. The wrong molecule can fail to address the sleep issue and can sometimes make the mood picture worse. The right molecule often addresses both. We unpacked the perimenopause-mood-medication overlap in the post on women quitting antidepressants after starting hormone therapy.
When Progestins Still Make Sense
This is not an argument that progestins should never be prescribed. There are legitimate uses for them.
Contraception is the primary one. The synthetic progestins were designed in part for reliable contraception, and they do that job well. The risk-benefit calculation for a 25-year-old preventing pregnancy is completely different from the calculation for a 50-year-old managing perimenopausal symptoms.
Certain bleeding disorders, endometrial protection in specific scenarios, and management of some gynecologic conditions also have evidence-based progestin protocols. The point is not that one category is good and the other is bad. The point is that the two categories are not interchangeable, and the choice should be intentional based on the clinical goal.
For hormone therapy aimed at perimenopausal symptom management and overall menopause care, bioidentical progesterone is generally the more evidence-aligned choice in 2026. The perimenopause treatment page covers the protocol approach in more detail.
How to Know What You Are Getting
Reading a prescription label is one way to know which category you have been prescribed. The generic name on the bottle will tell you:
“Progesterone” or “micronized progesterone” or “Prometrium” indicates bioidentical progesterone.
“Medroxyprogesterone acetate” or “MPA” or “Provera” indicates a progestin.
“Norethindrone,” “levonorgestrel,” “drospirenone,” “norgestimate,” or “desogestrel” all indicate progestins.
If you have ever been on hormone therapy or are currently on it and you are unsure which category you are taking, the label is the first place to check. The clinical effects of these molecules are not identical, and a switch under physician supervision can sometimes resolve issues that have been chalked up to “you just don’t tolerate hormones.”
The Bottom Line
The progesterone-progestin distinction is one of the clearer examples of where conventional medicine and optimization medicine genuinely diverge. Both categories have legitimate uses. They are not the same molecule, they do not produce the same effects, and the right choice depends on what you are actually trying to accomplish.
If your hormone therapy is not working the way you expected, or if you have been told that any side effect you are experiencing is “just hormones,” the formulation question is worth raising. Schedule a consultation and we will look at what you are actually taking and whether it matches the goal of the treatment.
